A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)
Running, not enrolling · Phase 3
Conditions studied: HER2-Positive Primary Breast Cancer, Residual Invasive Breast Cancer
In brief
Patients with HER2-positive primary breast cancer (BC) who do not achieve complete response after appropriate neoadjuvant therapy are at higher risk of disease recurrence. More effective treatment options are needed for this patient population. This study will examine the efficacy and safety of trastuzumab deruxtecan (T-DXd) compared with trastuzumab emtansine (T-DM1) in high-risk patients with residual invasive breast cancer following neoadjuvant therapy.
Key facts
- Study ID
- NCT04622319
- Run by
- Daiichi Sankyo
- People needed
- 1600
- Starts
- 2020-12-04
- Expected to finish
- 2028-06-20
- Last updated by the study team
- 2026-05-15
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Kaiser Permanente — Anaheim, California, United States
- Kaiser Permanente — Baldwin Park, California, United States
- Kaiser Permanente — Bellflower, California, United States
- Kaiser Permanente — Fontana, California, United States
- Orange Coast Blood and Cancer Care — Fountain Valley, California, United States
- Kaiser Permanente — Harbor City, California, United States
- Kaiser Permanente — Irvine, California, United States
- Long Beach Memorial TCI — Long Beach, California, United States
- Kaiser Permanente — Los Angeles, California, United States
- Kaiser Permanente — Ontario, California, United States
- Kaiser Permanente — Panorama City, California, United States
- Kaiser Permanente — Riverside, California, United States
- Kaiser Permanente — San Diego, California, United States
- Kaiser Permanente — San Marcos, California, United States
- Kaiser Permanente — West Los Angeles, California, United States
- Kaiser Permanente — Woodland Hills, California, United States
- SCRI FCS North- Altamonte — Altamonte Springs, Florida, United States
- SCRI FCS South- Bonita — Bonita Springs, Florida, United States
- SCRI FCS North- Brandon Cancer Center — Brandon, Florida, United States
- SCRI FCS South- North Fort Myers — Cape Coral, Florida, United States
- SCRI FCS North- Mease/Clearwater — Clearwater, Florida, United States
- SCRI FCS South — Fort Myers, Florida, United States
- SCRI FCS South- Colonial — Fort Myers, Florida, United States
- SCRI FCS South- Gladiolus — Fort Myers, Florida, United States
- The Oncology Institute of Hope & Innovation — Anaheim, California, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.